{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:47:23Z","timestamp":1791982043440,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.spen.2026.101295","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:24:42Z","timestamp":1779380682000},"page":"101295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapies for NORSE and FIRES"],"prefix":"10.1016","volume":"59","author":[{"given":"Kristen S.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Muscal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.spen.2026.101295_bib0001","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.spen.2026.101295_bib0002","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1528-1167.2010.02535.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood","volume":"51","author":"van Baalen","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.spen.2026.101295_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2019.12.002","article-title":"New-onset refractory status epilepticus: a retrospective cohort study","volume":"74","author":"Gugger","year":"2020","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.spen.2026.101295_bib0004","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/epi.14524","article-title":"Fueling the FIRES: hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome","volume":"59","author":"Farias-Moeller","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/acn3.51832","article-title":"CSF neopterin and quinolinic acid are biomarkers of neuroinflammation and neurotoxicity in FIRES and other infection-triggered encephalopathy syndromes","volume":"10","author":"Dale","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.spen.2026.101295_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2026.104512","article-title":"An increase in cerebrospinal fluid macrophage migration inhibitory factor levels in pediatric patients with acute neuroinflammatory diseases: a preliminary study","volume":"48","author":"Nasuno","year":"2026","journal-title":"Brain Dev"},{"issue":"1","key":"10.1016\/j.spen.2026.101295_bib0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.26627","article-title":"Cytokines in new-onset refractory status epilepticus predict outcomes","volume":"94","author":"Hanin","year":"2023","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0008","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/epi.17988","article-title":"Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: an interim analysis","volume":"65","author":"Jimenez","year":"2024","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.spen.2026.101295_bib0009","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/jnnp-2014-309388","article-title":"Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus","volume":"86","author":"Sakuma","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.spen.2026.101295_bib0011","article-title":"Neuroimmunology of status epilepticus","volume":"140","author":"Vezzani","year":"2023","journal-title":"Epilepsy Behav EB"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0012","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0013","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/epi.16275","article-title":"Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus","volume":"60","author":"Kothur","year":"2019","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.spen.2026.101295_bib0014","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/acn3.51229","article-title":"Anakinra usage in febrile infection related epilepsy syndrome: an international cohort","volume":"7","author":"Lai","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.spen.2026.101295_bib0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/acn3.51308","article-title":"Intrathecal dexamethasone therapy for febrile infection-related epilepsy syndrome","volume":"8","author":"Horino","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.spen.2026.101295_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/jnnp-2024-334285","article-title":"Prognosis prediction and immunotherapy optimisation for cryptogenic new-onset refractory status epilepticus","volume":"96","author":"Jang","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.spen.2026.101295_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1161161","article-title":"Investigating the genetic contribution in febrile infection-related epilepsy syndrome and refractory status epilepticus","volume":"14","author":"deCampo","year":"2023","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0018","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/acn3.51062","article-title":"Whole-exome and HLA sequencing in Febrile infection-related epilepsy syndrome","volume":"7","author":"Helbig","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.spen.2026.101295_bib0019","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1469-8749.2012.04435.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations","volume":"54","author":"Appenzeller","year":"2012","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0020","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ana.27100","article-title":"Polygenic landscape of cryptogenic new-onset refractory status epilepticus: a comprehensive whole-genome sequencing study","volume":"96","author":"Jang","year":"2024","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.spen.2026.101295_bib0021","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/epi.18008","article-title":"FADD gene pathogenic variants causing recurrent febrile infection-related epilepsy syndrome: case report and literature review","volume":"65","author":"Giovannini","year":"2024","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.spen.2026.101295_bib0022","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1111\/epi.18538","article-title":"De novo pathogenic CSF1R variant implicates microglial dysfunction in pathogenesis of febrile infection-related epilepsy syndrome","volume":"66","author":"Fisher","year":"2025","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.spen.2026.101295_bib0023","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1111\/epi.17397","article-title":"International consensus recommendations for management of new onset refractory status epilepticus (NORSE) incl. Febrile infection-related epilepsy syndrome (FIRES): statements and supporting evidence","volume":"63","author":"Wickstrom","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.spen.2026.101295_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/epi4.12447","article-title":"Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): a report from FIRES workshop","volume":"6","author":"Koh","year":"2021","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.spen.2026.101295_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000663","article-title":"Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient","volume":"7","author":"Cellucci","year":"2020","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0026","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bbi.2008.03.009","article-title":"The role of cytokines in the pathophysiology of epilepsy","volume":"22","author":"Vezzani","year":"2008","journal-title":"Brain Behav Immun"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0027","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2026.101295_bib0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2025.06.022","article-title":"Retrospective multicenter study on cryptogenic NORSE\/FIRES patients treated with anakinra","volume":"130","author":"Giussani","year":"2025","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.spen.2026.101295_bib0029","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/epi.17933","article-title":"Second-line immunotherapy in new onset refractory status epilepticus","volume":"65","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0030","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/epi.18014","article-title":"Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: an interim analysis","volume":"65","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.spen.2026.101295_bib0031","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0000000000200855","article-title":"Child neurology: initial presentation of PCDH19-related epilepsy with new-onset refractory status epilepticus and treatment with Anakinra","volume":"99","author":"Varughese","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2026.101295_bib0032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2020.10.009","article-title":"Successful treatment of pediatric FIRES with Anakinra","volume":"114","author":"Yang","year":"2021","journal-title":"Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.spen.2026.101295_bib0033","first-page":"135","article-title":"Febrile infection-related epilepsy syndrome treated successfully with Anakinra in a 21-year-old woman","volume":"118","author":"Westbrook","year":"2019","journal-title":"WMJ Publ State Med Soc Wis"},{"key":"10.1016\/j.spen.2026.101295_bib0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.seizure.2021.11.014","article-title":"Response to anakinra in new-onset refractory status epilepticus: a clinical case","volume":"94","author":"Palacios-Mendoza","year":"2022","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.spen.2026.101295_bib0035","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dmcn.14553","article-title":"New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome","volume":"62","author":"Specchio","year":"2020","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.spen.2026.101295_bib0036","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/acn3.51714","article-title":"Systemic inflammatory markers and EEG features of children with FIRES receiving anakinra","volume":"10","author":"Lai","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.spen.2026.101295_bib0037","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s12035-022-02725-6","article-title":"Neuroinflammation and proinflammatory cytokines in epileptogenesis","volume":"59","author":"Soltani Khaboushan","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.spen.2026.101295_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X20979253","article-title":"Interleukin-6 blockade with Tocilizumab in Anakinra-refractory febrile infection-related epilepsy syndrome (FIRES)","volume":"7","author":"Stredny","year":"2020","journal-title":"Child Neurol Open"},{"issue":"2","key":"10.1016\/j.spen.2026.101295_bib0039","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1535759719835363","article-title":"A new hose to extinguish the FIRES?","volume":"19","author":"Gaspard","year":"2019","journal-title":"Epilepsy Curr"},{"issue":"6","key":"10.1016\/j.spen.2026.101295_bib0040","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/epi.17591","article-title":"Treatment of new onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult","volume":"64","author":"Girardin","year":"2023","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.spen.2026.101295_bib0041","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/acn3.70120","article-title":"Observational study of Tocilizumab in children with Febrile infection-related epilepsy syndrome","volume":"12","author":"He","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"24","key":"10.1016\/j.spen.2026.101295_bib0042","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.2169\/internalmedicine.3392-23","article-title":"Treatment of cryptogenic new-onset refractory status epilepticus (C-NORSE) with Tocilizumab","volume":"63","author":"Nakamura","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.spen.2026.101295_bib0043","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.seizure.2025.11.019","article-title":"Tocilizumab for super-refractory status epilepticus in children with FIRES: a case series","volume":"134","author":"Murugesu","year":"2026","journal-title":"Seizure"},{"issue":"24","key":"10.1016\/j.spen.2026.101295_bib0044","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1212\/WNL.0000000000207068","article-title":"Bridging the gap: tailoring an approach to treatment in Febrile infection-related epilepsy syndrome","volume":"100","author":"Goh","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2026.101295_bib0045","article-title":"Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab","volume":"15","author":"Donnelly","year":"2021","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.spen.2026.101295_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578430","article-title":"IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis presenting as NORSE: a case report","volume":"395","author":"Yarimi","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.spen.2026.101295_bib0047","article-title":"Intrathecal Dexamethasone in Febrile infection-related epilepsy syndrome: a case report","volume":"13","author":"Mehta","year":"2023","journal-title":"Neurol Clin Pr"},{"issue":"2","key":"10.1016\/j.spen.2026.101295_bib0048","article-title":"Early intrathecal dexamethasone (IT-Dexa) associated with faster recovery and good outcome in an adolescent with febrile infection-related epilepsy syndrome (FIRES)","volume":"18","author":"Sudarsanan","year":"2025","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.spen.2026.101295_bib0049","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12028-025-02254-9","article-title":"Intrathecal Dexamethasone as a FIRES extinguisher: a 12-patient clinical experience with usage of Intrathecal Dexamethasone for Febrile infection-related epilepsy syndrome","volume":"43","author":"Farias-Moeller","year":"2025","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.spen.2026.101295_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2025.04.005","article-title":"Implementation of an institutional protocol for the use of intrathecal Dexamethasone for treatment-refractory pediatric neuroinflammatory disease","volume":"168","author":"Fisher","year":"2025","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2026.101295_bib0051","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/acn3.70011","article-title":"Combined systemic immunotherapy and intrathecal dexamethasone in Febrile infection related epilepsy Syndrome","volume":"12","author":"Fisher","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.spen.2026.101295_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.spen.2026.101295_bib0053","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.spen.2026.101295_bib0054","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200403","article-title":"Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling","volume":"12","author":"Guillemaud","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflammat"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909126000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909126000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:07:02Z","timestamp":1791979622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909126000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S1071909126000392"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2026.101295","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapies for NORSE and FIRES","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2026.101295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101295"}}